Evolus Shares Rise on Jump in Revenue

WSJ58minutes ago

Evolus Projects FDA Nod For Evolysse Gels Within 90 Days, Eyes Q2 2025 U.S. Rollout; Reports $79M Q4 2024 Revenue, FY24 Revenue $266.3M; Expects $345M-$355M Net Revenue And $230M-$240M Non-GAAP Expenses For 2025; Plans 8-10% Revenue From Evolysse,...

Benzinga08:18 ET

Evolus | 8-K: Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

SEC08:06 ET · Announcements

Express News | Evolus Inc: Maintains Projection for FY2025 Profitability

Reuters08:01 ET

Evolus Expects U.S. FDA Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels >EOLS

Dow Jones08:01 ET

Evolus 4Q Rev $79M >EOLS

Dow Jones08:01 ET